Journal article

Romosozumab/CDP7851 for the treatment of osteoporosis

Ie-Wen Sim, Peter R Ebeling

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD | Published : 2015

Abstract

Osteoporosis is an important worldwide health problem, conferring significant costs on healthcare. Current osteoporosis therapies are anti-resorptive and have proven anti-fracture efficacy, while there is a paucity of osteoanabolic therapies. Romosozumab is a humanized monoclonal antibody against sclerostin, an inhibitor of osteoblastic activity. Two-year follow-up data from initial clinical studies show rapid and robust increases in bone mineral density at all sites, except the wrist. Significant increases in bone formation markers have also been observed after administration of romosozumab. Notably, and unprecedented among any currently available therapy, this increase in bone formation is..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

The authors were supported by Monash University and National Health and Medical Research Council of Australia. PR Ebeling has received research funding from Amgen, Merck, Novartis, and Eli-Lilly and honoraria from Merck, Amgen, Pfizer, ViiV Healthcare, and GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.